Skip to main content

Table 2 Pathology of PDO-based xenografted liver metastases (PDOX-LM) models

From: A novel patient-derived organoids-based xenografts model for preclinical drug response testing in patients with colorectal liver metastases

Patient no.

Mean CEA, ng/ml

No. of grafts in spleen/total no. of grafts (%)

No. of grafts in murine liver/total no. of grafts (%)

No. of xenografted liver metastases, median (range)

3-week

5-week

7-week

mCRC

 1#

66.4

1834.8

12066.8

4/4 (100)

3/4 (75)

2 (2, 2)

 2#

93.2

202.4

424.6

3/4 (75)

3/4 (75)

2 (2, 4)

 3#

36.0

326.0

422.0

3/4 (75)

3/4 (75)

2 (2, 3)

 4#

277.8

1226.4

1775.4

4/4 (100)

3/4 (75)

3 (2, 4)

 5#

42.2

106.0

322.2

4/4 (100)

2/4 (50)

3.5 (2, 5)

 6#

11.4

44.2

306.6

4/4 (100)

1/4 (25)

4 (4, 4)

CRC

 7#

6.4

76.0

89.4

4/4 (100)

0/4 (0)

/

 8#

11.2

16.6

13.2

3/4 (75)

0/4 (0)

/

 9#

25.6

126.8

424.4

3/4 (75)

0/4 (0)

/

 10#

2.2

2.8

11.8

2/4 (50)

0/4 (0)

/

 11#

1.2

36.6

36.2

4/4 (100)

0/4 (0)

/

 12#

1.8

2.2

4.2

2/4 (50)

0/4 (0)

/